Synopsis
0
CEP/COS
0
VMF
0
EDQM
0
USP
0
JP
0
Others
0
Australia
DRUG PRODUCT COMPOSITIONS0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
API SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
USDMF
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]EU WC
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]NDC API
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Listed Suppliers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]API Reference Price
API/FDF Prices: Book a Demo to explore the features and consider upgrading later
API Imports and Exports
Drugs in Development
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]INTERMEDIATE SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDF Dossiers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDA Orange Book
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Europe
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Canada
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]DRUG PRODUCT COMPOSITIONS
DOSAGE - INJECTABLE;INTRAVENOUS - EQ 100MG BA...DOSAGE - INJECTABLE;INTRAVENOUS - EQ 100MG BASE/VIAL
USFDA APPLICATION NUMBER - 21506
DOSAGE - INJECTABLE;INTRAVENOUS - EQ 50MG BAS...DOSAGE - INJECTABLE;INTRAVENOUS - EQ 50MG BASE/VIAL
USFDA APPLICATION NUMBER - 21506
DOSAGE - SOLUTION;INTRAVENOUS - EQ 100MG BASE...DOSAGE - SOLUTION;INTRAVENOUS - EQ 100MG BASE/100ML (EQ 1MG BASE/ML)
USFDA APPLICATION NUMBER - 216142
DOSAGE - SOLUTION;INTRAVENOUS - EQ 150MG BASE...DOSAGE - SOLUTION;INTRAVENOUS - EQ 150MG BASE/150ML (EQ 1MG BASE/ML)
USFDA APPLICATION NUMBER - 216142
DOSAGE - SOLUTION;INTRAVENOUS - EQ 50MG BASE/...DOSAGE - SOLUTION;INTRAVENOUS - EQ 50MG BASE/50ML (EQ 1MG BASE/ML)
USFDA APPLICATION NUMBER - 216142
Digital Content
DATA COMPILATION #PharmaFlow
NEWS #PharmaBuzz
Global Sales Information
US Medicaid Prescriptions
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Market Place
ABOUT THIS PAGE
88
PharmaCompass offers a list of Micafungin API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Micafungin manufacturer or Micafungin supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Micafungin manufacturer or Micafungin supplier.
PharmaCompass also assists you with knowing the Micafungin API Price utilized in the formulation of products. Micafungin API Price is not always fixed or binding as the Micafungin Price is obtained through a variety of data sources. The Micafungin Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Mycamine manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Mycamine, including repackagers and relabelers. The FDA regulates Mycamine manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Mycamine API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Mycamine manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Mycamine supplier is an individual or a company that provides Mycamine active pharmaceutical ingredient (API) or Mycamine finished formulations upon request. The Mycamine suppliers may include Mycamine API manufacturers, exporters, distributors and traders.
click here to find a list of Mycamine suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Mycamine DMF (Drug Master File) is a document detailing the whole manufacturing process of Mycamine active pharmaceutical ingredient (API) in detail. Different forms of Mycamine DMFs exist exist since differing nations have different regulations, such as Mycamine USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Mycamine DMF submitted to regulatory agencies in the US is known as a USDMF. Mycamine USDMF includes data on Mycamine's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Mycamine USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Mycamine suppliers with USDMF on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The Mycamine Drug Master File in Japan (Mycamine JDMF) empowers Mycamine API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the Mycamine JDMF during the approval evaluation for pharmaceutical products. At the time of Mycamine JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of Mycamine suppliers with JDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a Mycamine Drug Master File in Korea (Mycamine KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Mycamine. The MFDS reviews the Mycamine KDMF as part of the drug registration process and uses the information provided in the Mycamine KDMF to evaluate the safety and efficacy of the drug.
After submitting a Mycamine KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Mycamine API can apply through the Korea Drug Master File (KDMF).
click here to find a list of Mycamine suppliers with KDMF on PharmaCompass.
A Mycamine written confirmation (Mycamine WC) is an official document issued by a regulatory agency to a Mycamine manufacturer, verifying that the manufacturing facility of a Mycamine active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Mycamine APIs or Mycamine finished pharmaceutical products to another nation, regulatory agencies frequently require a Mycamine WC (written confirmation) as part of the regulatory process.
click here to find a list of Mycamine suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Mycamine as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Mycamine API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Mycamine as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Mycamine and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Mycamine NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Mycamine suppliers with NDC on PharmaCompass.
Mycamine Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Mycamine GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Mycamine GMP manufacturer or Mycamine GMP API supplier for your needs.
A Mycamine CoA (Certificate of Analysis) is a formal document that attests to Mycamine's compliance with Mycamine specifications and serves as a tool for batch-level quality control.
Mycamine CoA mostly includes findings from lab analyses of a specific batch. For each Mycamine CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Mycamine may be tested according to a variety of international standards, such as European Pharmacopoeia (Mycamine EP), Mycamine JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Mycamine USP).
